Better Blood Sugar, Better Blood Pressure with Hintonia latiflora
For the past thirty years, the prevalence of metabolic syndrome has increased across every demographic. Aside from high blood sugar, those with metabolic syndrome may also have issues with weight, cholesterol levels, and elevated blood pressure. One herb has the potential to address this deadly combination of disease symptoms: Hintonia latiflora.
Prior research with Hintonia has shown that bark extracts from the plant help lower blood sugar levels in individuals with diabetes or pre-diabetes. In those same studies, the botanical normalized cholesterol and triglycerides as well. This scientific study shows that it may be just the right herb for lowering blood pressure, too.
The very compound that helps regulate and lower blood glucose levels, coutareagenin, was shown in this research to act as a vasodilator as well. That means that it helps blood vessels remain more “open”, allowing blood to flow more easily. Considering the damage to blood vessels that elevated blood sugar can cause, the fact that Hintonia can address these multiple aspects of diabetes, including related cardiovascular issues, provides great hope for anyone dealing with these conditions.
Vierling C, Baumgartner CM, Bollerhey M, Erhardt WD, Stampfl A, Vierling W. The vasodilating effect of a Hintonia latiflora extract with antidiabetic action. Phytomedicine. 2014 Oct 15;21(12):1582-6.
In the present study, it is shown for the first time that an extract of Hintonia latiflora (HLE) which is used as an antidiabetic herbal medicine, is not only able to decrease blood glucose concentration but additionally exerts a vasodilating effect. Accordingly, this extract might have a positive influence on diabetes-associated dysfunction of blood vessels. The vasodilating effect was demonstrated in vitro in aortic rings of guinea pigs as well as in vivo in rabbits. Aortic rings pre-contracted with noradrenaline (NA) could completely be relaxed by HLE (EC50: 51.98 mg/l). In contrast, potassium-induced contractions were not diminished by HLE. Therefore, it can be suggested that the vasodilating effect of HLE is primarily the result of an inhibition of G protein-induced increase in intracellular calcium and not of a blockade of voltage-operated L-type calcium channels. The neoflavonoid coutareagenin (COU), a constituent of HLE which in part is responsible for the blood glucose-lowering effect of HLE, also relaxed NA-induced contractions of aortic rings (EC50: 32.55 mg/l) and only weakly inhibited potassium-induced contractions. Experiments in aortic rat cells revealed that calcium transients evoked by vasopressin were suppressed by 60 mg/l COU supporting the idea of an inhibition of G protein-induced intracellular calcium release by a constituent of HLE. To study the effect of HLE on vascular tone under in vivo conditions, ultrasound measurements were carried out in conscious rabbits which received a single oral dose of HLE. Under the influence of HLE, a vasodilation combined with a lowering of blood flow velocity could be observed in the abdominal aorta and the common carotid artery. Additionally, a decrease in blood glucose concentration in the HLE group occurred. The combination of a blood glucose-lowering with a vasodilating effect may be helpful for reducing angiopathies, typical long-term complications in patients with diabetes mellitus.
Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis 2017;14:160287.
Introduction: Metabolic syndrome is a cluster of cardiometabolic risk factors associated with increased risk of multiple chronic diseases, including cancer and cardiovascular disease. The objectives of this study were to estimate the prevalence of metabolic syndrome overall, by race and sex, and to assess trends in prevalence from 1988 through 2012.
Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) for 1988 through 2012. We defined metabolic syndrome as the presence of at least 3 of these components: elevated waist circumference, elevated triglycerides, reduced high-density lipoprotein cholesterol, high blood pressure, and elevated fasting blood glucose. Data were analyzed for 3 periods: 1988–1994, 1999–2006, and 2007–2012.
Results: Among US adults aged 18 years or older, the prevalence of metabolic syndrome rose by more than 35% from 1988–1994 to 2007–2012, increasing from 25.3% to 34.2%. During 2007–2012, non-Hispanic black men were less likely than non-Hispanic white men to have metabolic syndrome (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.66–0.89). However, non-Hispanic black women were more likely than non-Hispanic white women to have metabolic syndrome (OR, 1.20; 95% CI, 1.02–1.40). Low education level (OR, 1.56; 95% CI, 1.32–1.84) and advanced age (OR, 1.73; 95% CI, 1.67–1.80) were independently associated with increased likelihood of metabolic syndrome during 2007–2012.
Conclusion: Metabolic syndrome prevalence increased from 1988 to 2012 for every sociodemographic group; by 2012, more than a third of all US adults met the definition and criteria for metabolic syndrome agreed to jointly by several international organizations.
Read the complete article: Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States